Information Provided By: 
Fly News Breaks for March 17, 2017
AMGN, MDCO
Mar 17, 2017 | 11:50 EDT
JPMorgan analyst Jessica Fye believes today's cholesterol data from Amgen (AMGN) do not justify the downward move in shares of The Medicines Co. (MDCO). The analyst sees a "clear clinical benefit" from Amgen's Repatha, which she thinks support the likelihood of clinical success and value for Medicines' inclisiran. The analyst remains comfortable with her 70% probability of success and $1.6B peak sales forecast for inclisiran. Fye keeps an Overweight rating on Medicines and believes the 18% selloff today is overdone.
News For MDCO;AMGN From the Last 2 Days
There are no results for your query MDCO;AMGN
